European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma
The Pharma Data
APRIL 28, 2021
The P hase 3 IKEMA trial’s finding that the addition of Sarclisa to this regimen reduce d the risk of progression or death by nearly half formed the basis for this important EC approval. ”. 3 João C, Costa C, Coelho I, Vergueiro MJ, Ferreira M, Silva MG. Adamson, Global Development Head, Oncology and Pediatric Innovation at Sanofi.
40 
Let's personalize your content